|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Negro F: Natural history of NASH and HCC.
Liver Int. 40 (Suppl 1):S72–S76. 2020. View Article : Google Scholar
|
|
3
|
Nahon P, Vibert E, Nault JC, Ganne-Carrie
N, Ziol M and Seror O: Optimizing curative management of
hepatocellular carcinoma. Liver Int. 40 (Suppl 1):S109–S115. 2020.
View Article : Google Scholar
|
|
4
|
Refolo MG, Messa C, Guerra V, Carr BI and
D'Alessandro R: Inflammatory mechanisms of HCC development. Cancers
(Basel). 12:6412020. View Article : Google Scholar
|
|
5
|
Mohs A, Kuttkat N, Reissing J, Zimmermann
HW, Sonntag R, Proudfoot A, Youssef SA, de Bruin A, Cubero FJ and
Trautwein C: Functional role of CCL5/RANTES for HCC progression
during chronic liver disease. J Hepatol. 66:743–753. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hayden MS and Ghosh S: Shared principles
in NF-kappaB signaling. Cell. 132:344–362. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoffmann A, Levchenko A, Scott ML and
Baltimore D: The IkappaB-NF-kappaB signaling module: Temporal
control and selective gene activation. Science. 298:1241–1245.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J and Chen ZJ: Regulation of NF-κB by
ubiquitination. Curr Opin Immunol. 25:4–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Q and Verma IM: NF-kappaB regulation in
the immune system. Nat Rev Immunol. 2:725–734. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Y, Lu L, Tu J, Zhang J, Xiong T, Fan W,
Wang J, Li M, Chen Y, Steggerda J, et al: Reciprocal regulation
between forkhead Box M1/NF-kB and methionine adenosyltransferase 1A
drives liver cancer. Hepatology (Baltimore, Md.). Feb 21–2020.doi:
10.1002/hep.31196. Online ahead of print. View Article : Google Scholar
|
|
11
|
Ghosh S and Karin M: Missing pieces in the
NF-kappaB puzzle. Cell. 109 (Suppl):S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gupta SC, Awasthee N, Rai V, Chava S,
Gunda V and Challagundla KB: Long non-coding RNAs and nuclear
factor-κB crosstalk in cancer and other human diseases. Biochim
Biophys Acta Rev Cancer. 1873:1883162020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Borg JP, Marchetto S, Le Bivic A,
Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adélaïde J,
Margolis B and Birnbaum D: ERBIN: A basolateral PDZ protein that
interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol.
2:407–414. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dan L, Shi M, Duan H, Han C and Guo N:
Erbin, a negative regulator in diverse signal pathways. Curr
Protein Pept Sci. 11:759–764. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang H, Song Y, Wu Y, Guo N, Ma Y and
Qian L: Erbin loss promotes cancer cell proliferation through
feedback activation of Akt-Skp2-p27 signaling. Biochem Biophys Res
Commun. 463:370–376. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang YZ, Zang M, Xiong WC, Luo Z and Mei
L: Erbin suppresses the MAP kinase pathway. J Biol Chem.
278:1108–1114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hu Y, Chen H, Duan C, Liu D, Qian L, Yang
Z, Guo L, Song L, Yu M, Hu M, Shi M and Guo N: Deficiency of Erbin
induces resistance of cervical cancer cells to anoikis in a
STAT3-dependent manner. Oncogenesis. 2:e522013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu H, Yao S, Zhang S, Wang JR, Guo PD, Li
XM, Gan WJ, Mei L, Gao TM and Li JM: Elevated expression of Erbin
destabilizes ERalpha protein and promotes tumorigenesis in
hepatocellular carcinoma. J Hepatol. 66:1193–1204. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McDonald C, Chen FF, Ollendorff V, Ogura
Y, Marchetto S, Lécine P, Borg JP and Nuñez G: A role for Erbin in
the regulation of Nod2-dependent NF-kappaB signaling. J Biol Chem.
280:40301–40309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Department of Medical Administration,
National Health Commission of the People's Republic of China:
Guidelines for diagnosis and treatment of primary liver cancer in
China (2019 edition). Zhonghua Gan Zang Bing Za Zhi. 28:112–128.
2020.(In Chinese). PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dolcet X, Llobet D, Pallares J and
Matias-Guiu X: NF-κB in development and progression of human
cancer. Virchows Arch. 446:475–482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X,
Lin L, Yao H, Su F, Li D, et al: A cytoplasmic NF-κB interacting
long noncoding RNA blocks IκB phosphorylation and suppresses breast
cancer metastasis. Cancer Cell. 27:370–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma C, Zuo W, Wang X, Wei L, Guo Q and Song
X: Lapatinib inhibits the activation of NF-κB through reducing
phosphorylation of IκB-α in breast cancer cells. Oncol Rep.
29:812–818. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ataie-Kachoie P, Badar S, Morris DL and
Pourgholami MH: Minocycline targets the NF-κB Nexus through
suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol
Cancer Res. 11:1279–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rhoads MG, Kandarian SC, Pacelli F,
Doglietto GB and Bossola M: Expression of NF-kappaB and IkappaB
proteins in skeletal muscle of gastric cancer patients. Eur J
Cancer. 46:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN,
Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, et al: Inhibition of the
NF-κB pathway by nafamostat mesilate suppresses colorectal cancer
growth and metastasis. Cancer Lett. 380:87–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Feld JJ and Krassenburg LAP: What comes
first: Treatment of viral hepatitis or liver cancer? Dig Dis Sci.
64:1041–1049. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Clevers H: At the crossroads of
inflammation and cancer. Cell. 118:671–674. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pikarsky E, Porat RM, Stein I, Abramovitch
R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and
Ben-Neriah Y: NF-kappaB functions as a tumour promoter in
inflammation-associated cancer. Nature. 431:461–466. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Elsharkawy AM and Mann DA: Nuclear
factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.
Hepatology. 46:590–597. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Stevens PD, Wen YA, Xiong X, Zaytseva YY,
Li AT, Wang C, Stevens AT, Farmer TN, Gan T, Weiss HL, et al: Erbin
suppresses KSR1-mediated RAS/RAF signaling and tumorigenesis in
colorectal cancer. Cancer Res. 78:4839–4852. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liu D, Shi M, Duan C, Chen H, Hu Y, Yang
Z, Duan H and Guo N: Downregulation of Erbin in Her2-overexpressing
breast cancer cells promotes cell migration and induces trastuzumab
resistance. Mol Immunol. 56:104–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie CM, Wei D, Zhao L, Marchetto S, Mei L,
Borg JP and Sun Y: Erbin is a novel substrate of the Sag-βTrCP E3
ligase that regulates KrasG12D-induced skin tumorigenesis. J Cell
Biol. 209:721–737. 2015. View Article : Google Scholar : PubMed/NCBI
|
